1. Scrip
  2. >>R&D
  3. >>Clinical Trials

Pfizer’s Mixed Readout Places Doubt On Oral GLP-1 For Obesity

 
• By Joseph Haas

Twice-daily danuglipron reduced weight in a Phase IIb trial but with a poor side-effect profile and high discontinuation rates. Pfizer is working on a once-daily formulation it hopes will offer better tolerability.

Pfizer sign
Pfizer puts hopes for oral GLP-1 agonist on daily formulation work

The bad news clearly outweighed the good from Pfizer Inc.’s Phase IIb trial of its twice-daily, oral GLP-1 agonist danuglipron for obesity on 1 December, as the pharma said it would not advance the drug into Phase III in its current formulation. Pfizer still is holding out hope for a once-daily formulation it is developing, however, pointing to a pharmacokinetic data readout it expects during the first half of 2024.

Key Takeaways

  • Pfizer’s oral GLP-1 agonist danuglipron met statistical significance for weight loss in a Phase IIb study, but with a grim tolerability profile.

Danuglipron is Pfizer’s best hope for now at competing in the burgeoning obesity space, where Novo Nordisk A/S and...

More from Clinical Trials

Altimmune’s Phase IIb MASH Data Send Share Price Plunging

 
• By Joseph Haas

Altimmune’s stock price did not recover on June 27, after a 57% dip the day before, despite efforts to position pemvidutide as both resolving MASH and offering weight loss.

What Incyte Investors Expect From New CEO Bill Meury

 
• By Andrew McConaghie

Fresh from having sold Anthos to Novartis, the new CEO is expected to update the oncology and dermatology-focused firm's strategy.

Bayer Buoyant After EU Nod For Twice-Yearly Eylea

 
• By Kevin Grogan

Green light follows a recent rejection by the US FDA to partner Regeneron's request for an extension to the dosing interval.

Veru’s Enobosarm Market Potential Enhanced By New Obesity Data

 
• By Aakash Babu

The late-stage biotech posted results from the maintenance extension portion of its Phase IIb QUALITY trial in which enobosarm reduced weight regain and helped preserve lean mass in patients who discontinued their semaglutide weight-loss treatment.

More from R&D

GSK, Bharat On Shigella Vaccine Phase II Data Timelines, Malaria Vaccine Price Halving

 
• By Vibha Ravi

GSK tells Scrip about timelines for data expected from two Phase II trials for its Bharat Biotech-partnered shigella vaccine candidate, which puts it ahead of Limmatech/Valneva. Meanwhile, a global-first malaria vaccine, also partnered with Bharat, sees an over 50% price cut

Pfizer’s Hympavzi Poised For Broader Hemophilia Label

 
• By Alaric DeArment

The drugmaker announced positive topline results for the drug in hemophilia A and B patients with inhibitors, on top of the existing approval for patients without inhibitors.

Pharma Growth And Biotech Squeeze Will Shape Sector To 2030, Evaluate Forecasts

 
• By Andrew McConaghie

Evaluate’s five-year forecast sees steady growth for big pharma despite recent political turmoil but tougher times ahead for the ‘have nots’ of biotech.